A failure of protein degradation may underpin Lewy body disease (LBD) where α-synuclein is assimilated into the pathognomic Lewy bodies and Lewy neurites. We investigated histological alterations in lysosomes and autophagosomes in the substantia nigra (SN) and cingulate gyrus (CG) in 34 patients with LBD employing antibodies against phosphorylated α-synuclein and lysosomal (lysosomal associated membrane proteins 1 and 2 (LAMP-1 and LAMP-2), cathepsin D (CTSD)) and autophagosomal (microtubule-associated protein light chain 3α (LC3A)) proteins. Immunostained sections were qualitatively and semi-quantitatively assessed for the appearance, distribution and intensity of staining. Four LBD patients had mutations in GBA1. There was significantly less LAMP-1, LAMP-2 and CTSD immunostaining in neurons of the SN in LBD cases compared to control cases and marginally less LAMP-1 in patients with GBA1 mutations compared to those without. Loss of LAMP-1 and CTSD immunoreactivity correlated with cell loss from the SN. There were no changes in LC3A immunoreactivity in the SN, nor any major changes in the CG, or glial cell activity in the SN and CG, for any of the markers. A proportion of amyloid plaques in both the LBD and control cases was immunoreactive for LAMP-1 and LAMP-2, but not CTSD or LC3A proteins. These immunohisochemical features were seen in glial cells, which were negative for amyloid-β. Alterations in lysosomal structure or function, but not macroautophagy, may underpin the pathogenesis of LBD.
INTRODUCTION
Alzheimer's disease (AD) and Lewy body disease (LBD) are the most common neuropathological causes of neurodegenerative dementia. Although they share overlapping clinical features, each has a distinctive phenotype with LBD showing either motor predominant (Parkinson's disease (PD) and Parkinson's disease dementia (PDD)) or cognitive (dementia with Lewy bodies (DLB)) presentations. Clinically, DLB most commonly presents as episodic confusion and progressive cognitive impairment with significant deficits in attention and visuospatial function. 1, 2 Patients often experience visual hallucinations, and most suffer some degree of parkinsonism, especially in later stages of the disorder. 1 A defining pathological feature of both PD and DLB is atrophy of the pars compacta of the substantia nigra (SN), owing to loss of dopaminergic neurons, and the presence of proteinaceous inclusions, composed of the presynaptic membrane protein α-synuclein, termed Lewy bodies (LB) and Lewy neurites (LN) in surviving nerve cell bodies and their processes, respectively. 3 It is now well known that missense mutations in the gene encoding α-synuclein (SNCA) cause a rare familial autosomal dominant form of PD. 4 Moreover, polymorphisms in the Rep1 promoter region of SNCA are associated with an increased risk of sporadic PD. 5 Additionally, triplication and duplication of the SNCA gene cause a hereditary early and late-onset parkinsonism, respectively, where the SNCA gene dosage is directly correlated with disease progression. 6 Although α-synuclein is known to be localized to presynaptic terminals, its physiological function is still poorly understood. While loss of normal α-synuclein function may contribute to pathogenesis, it is widely believed that changes in α-synuclein result in a toxic gain-offunction due to their aggregation into highly reactive soluble oligomers. Hence, it is crucial that toxic protein aggregates are either prevented from forming or cleared from the cell, particularly in post-mitotic cells such as neurons. All cells possess highly effective protein quality control mechanisms to prevent this toxic aggregation. The first lines of defense are molecular chaperones that bind hydrophobic residues, preventing aggregation with other misfolded proteins and promoting refolding into the native conformation. 7 In states of cellular stress where massive protein misfolding may occur, the capacity of these chaperones to refold proteins becomes overwhelmed and these misfolded species are instead targeted to protein degradation (proteolytic) systems where they are eliminated. In neurons, there are two major proteolytic systems that collectively act to remove these potentially lethal conformers; the ubiquitin-proteasome system (UPS) and the autophagylysosomal pathway (ALP), of which key elements involve: (i) endoplasmic reticulum-associated degradation (ERAD), in which misfolded proteins are recognized in the endoplasmic reticulum and tagged with ubiquitin; 8 (ii) the UPS in which polyubiquitin-tagged proteins are chaperoned to the proteasome and enzymatically cleaved into amino acids; 9 (iii) macroautophagy whereby protein aggregates too large for UPS and ERAD are surrounded by vesicles (autophagosomes) and transported to lysosomes resulting in fusion and lysosomal enzymatic degradation; 10, 11 (iv) microautophagy in which aggregates/ organelles are sequestered directly by the lysosome through invaginations from its membrane; 12 (v) chaperone-mediated autophagy (CMA) in which proteins are transported to the lysosome via chaperone proteins in the absence of vesicular containment; 13 and (vi) endosomal sorting in which endocytosed products are targeted back to the cell surface, to lysosomes for degradation or exported from the cell as exosomes. 14 There is good evidence that basic failures within proteolytic pathways, particularly those involving UPS, result in the accumulation of aggregated forms of α-synuclein, and therefore may underpin the pathogenesis of LBD. For example, LB are highly ubiquitinated 10 and a number of proteasomal subunits have been found in LB, suggesting that proteins in these inclusions were marked for clearance, but cannot be degraded by UPS. 15 Mutations in the PARK2 gene encoding Parkin, an E3 ubiquitin ligase, cause an autosomal recessive form of early-onset PD 11 and missense mutations in the PARK5 gene, encoding ubiquitin C-terminal hydrolase-L1 (UCH-L1), cause a familial form of PD. 12 Reduced expression of proteasomal subunits has been reported within the SN of patients with PD 13, 14 and DLB, 16 and knockdown of 26S proteasome function leads to neurodegeneration. 17 Conversely, other studies point to a dysfunction of lysosomal pathways. For example, Gaucher's disease is a rare lysosomal storage disease caused by homozygous mutations in the GBA1 gene encoding the lysosomal hydrolytic enzyme glucosylceramidase, leading to toxic accumulation of its substrate (glucosylceramide) within lysosomes. 18 Genome-wide association studies have shown a strong association between heterozygous GBA1 mutations and PD 19 and DLB. 20, 21 Patients with PD were more than five times more likely to have a GBA1 mutation than controls, and patients with DLB were more than eight times more likely to have a GBA1 mutation. Pathological studies suggest that GBA1 mutation carriers are more likely to show DLB rather than PD pathology. 22 While bulk delivery of specific cargo to the lysosome can be performed by the autophagosome, CMA is orchestrated by molecular chaperones which recognize and bind to a KFERQ motif exposed upon misfolding, delivering the cargo directly to the lysosome one molecule at a time. 23 Lysosomal chaperones then pull the cargo into the lysosomal lumen where it is digested by acid hydrolases. 24 Importantly, α-synuclein is one such protein that contains a KFERQ motif, suggesting that it may normally be cleared by CMA. Wild-type α-synuclein can be efficiently degraded by CMA in vitro, although the aggregationprone A53T and A30P mutants are not efficiently translocated into the lysosome despite binding to lysosomal associated membrane protein (LAMP)-2A with high affinity. 25 The poor uptake of A53T and A30P α-synuclein into lysosomes may be a result of their aggregation. Accumulation of α-synuclein toxic conformers may be determined by the balance between the rates of α-synuclein synthesis, aggregation and clearance. Clearance of α-synuclein is executed by both the proteasome and lysosome: the UPS and CMA clear unmodified α-synuclein, while selective and constitutive autophagy are employed to degrade α-synuclein aggregates. Crosstalk between these proteolytic pathways helps to achieve protein homeostasis, as dysfunction in one leads to the upregulation of another. Hence, pathogenesis of DLB may involve successive failures of the UPS, CMA and autophagy to clear α-synuclein species. Against this background, the present investigation aimed to identify changes within the ALP in patients with LBD using marker proteins such as LAMP-1 and LAMP-2, cathepsin D (CTSD) and the microtubule associated protein 1A/1B-light chain α (LC3A) to index the function of lysosomes and autophagosomes, respectively). LAMP-1 appears to be a structural glycoprotein which maintains the structural integrity if the lysosomal membrane, but also shows colocalization with the autophagosomal marker LC3A, implying it has a role in autophagolysosome fusion. 26 LAMP-2 is essential for CMA. In this, the chaperone protein Hsc70 binds to KFERQ motifs, that are exposed when proteins suffer insults to their structural integrity, forming a translocation complex with LAMP-2A creating a pore through which to thread the protein intended for degradation. 26 CTSD is a lysosomal aspartictype protease which degrades aggregates delivered to the lysosome via CMA or endocytosis. 27 Neuromelanincontaining neurons of the SN and pyramidal cells of the cingulate gyrus (CG) were assessed qualitatively and semiquantitatively for the presence, intracellular distribution and relative staining intensity of these proteins. These cell types were chosen because of their propensity to form aggregations of α-synuclein in the form of LB and LN. 1, 2, 28, 29 In so doing, protein degradation was assessed at different levels with LAMP-1 acting as a marker of lysosomal number, LAMP-2 as a marker of CMA and lysosomal function, CTSD as a marker of lysosomal protein degradation activity and LC3A as a marker of autophagosomal activity.
MATERIALS AND METHODS

Patients
The study consisted of a group of 34 patients with pathologically confirmed LBD 1,2,28,29 (patients #1-34) and 10 control subjects free from neurological and psychiatric illness and significant neuropathological changes (patients #35-44) (see Table S1 ). Clinically, of the 34 patients with LBD, eight had been diagnosed as having DLB, five with PDD, 13 with Alzheimer's disease, two with vascular dementia, two with frontotemporal dementia and two with unspecified dementia; in two patients dementia had not been clinically ascribed and these in life had been considered to be cognitively normal (see Table S1 ). Table 1) . Of the 10 control subjects, five were male and five were female. Mean age at death in these was 85.4 AE 4.8 years (range, 76-91 years). As a group, the controls were therefore slightly, but significantly (P = 0.034), older than the LBD patients (Table 1) .
Histological methods
Blocks of the CG and SN were cut from fixed brain tissues of all the 34 LBD cases and the control cases and processed into paraffin wax. Six-micrometer-thick sections were mounted onto glass slides, and immunostained for α-synuclein phosphorylated at Ser129 using the antipsyn1175 antibody 31 
Pathological assessment
Immunostained sections were analyzed qualitatively and specific features were noted such as the intracellular Individual scores for LB and LN frequency in SN and CG were summated for each area separately, and then collectively, to give an area and overall score for LB pathology. For each area, from each LB and LN score, a maximum LB pathology score of six could be achieved, and therefore, across both regions combined a maximum overall LB pathology score of 12 was attainable.
The extent of SN degeneration (SND) was also assessed in these sections according to:
0. High density of clearly defined neuromelanin containing neurones 1. Mild loss of nigral cells with some residual extracellular neuromelanin deposits 2. Moderate loss of nigral cells with frequent extracellular neuromelanin deposits 3. Very few remaining neuromelanin containing neurones.
The degree of LAMP-1, LAMP-2, CTSD and LC3A immunostaining of surviving neurones of SN and CG, and glial cells in both regions, was assessed semi-quantitatively irrespective of the degree of nerve cell loss (assessed as above). In order to do this, images of SN and CG were captured at ×40 microscope objective magnification, using a Leica DMR light microscope, and subsequently analyzed on Corel PaintShop Pro X7 which allowed significant zoom in order to assist in distinguishing between similar levels of staining intensity.
A four-point grading system was employed: Many amyloid plaques present with extensive involvement of basal structures and cerebellum/severe CAA affecting all leptomeningeal, and some parenchymal, vessels in occipital lobe and other vessels in the cerebellum.
The number of plaques (but not CAA) immunostained by all four ALP markers was also assessed using the above scoring system.
In order to minimize intra-observer subjectivity and maximize accuracy of grading, semi-quantitative analyses for each pathological measure were performed by a single investigator (RG or DMAM) who also devised the grading systems employed. For each assessment, cases were graded three times blind to previous results and any discrepancies recorded. Discrepancies were reviewed closely and scores and grading systems were adjusted by consensus. Random samples for each assessment were subsequently taken and re-graded blind to previous results obtained to test the reproducibility of the scores and to test the reliability of the grading systems. Moreover, to assess inter-observer variability, a subset of 20 immunostained cases for each measure, selected at random, was chosen for independent scoring by both observers. This showed good agreement between all pairs of scores (κ ≥ 0.65, P = 0.000 in each instance), with 75% of scores being the same, and no score between cases differing by more than one grade in any pairwise comparison. Hence, use of these particular scoring systems show robust agreement when employed either by both highly (DMAM) or lesser experienced (RG) observers.
Genetic analysis
DNA was extracted from frozen samples of the cerebellum or frontal cortex for all except one LBD patient, and APOE genotype was determined. 34 Four of the LBD cases (two male and two female) (patients#1, 3, 21 and 22) possessed mutations in the GBA1 gene, as reported elsewhere. 20 Ten LBD patients were known to be free from mutations in the GBA1 gene, 20 but sequencing of GBA1
had not been performed in the remaining 10 LBD patients (see Table S1 ).
Statistical analysis
Rating data was entered into an Excel spreadsheet and analyzed using Statistical Package for Social Sciences (SPSS) software (version 17.0; SPSS inc., Chicago, IL, USA). Comparisons of semi-quantitative scores for intensity of immunostaining in SN and CG were performed using Mann-Whitney U-test to identify significant differences in staining between LBD patients and controls, and between LBD patients with full-blown AD pathology and those with lesser amounts of Alzheimer-type pathological changes, not meeting pathological criteria for AD. The Spearman rank correlation test was performed to identify significant correlations between data sets. Comparisons of age at onset, age at death and duration of illness were performed using Student's t-test. Comparisons of APOE allele frequency were made by Chi-square test or Fisher exact text, as appropriate. In correlation tests, in order to avoid type 1 errors from multiple testing, significance levels were stringently set at P < 0.01. In all other instances, significance levels were set at P < 0.05.
RESULTS
Neuropathological characterization
All 34 LBD patients showed some degree of Alzheimertype pathology in their brain. Tau pathology, in the form of neurofibrillary tangles, neuropil threads and neuritic plaques, was present in the hippocampus and amygdala, and to varying extents in the cerebral cortex, in all 34 patients. In 20 of these (patients #1-20), tau pathology was mild to moderate in extent, and less than Braak tau stage V in all instances, with nine patients showing Braak tau stage II or less. The remaining 14 patients (patients #21-34) showed extensive tau pathology at Braak tau stages V or VI (see Table S1 ). One patient (patient #11) also showed additional tau pathology in the temporal lobe in the form of argyrophilic grain disease. All except one LBD patient (patient #12) showed some degree of amyloid pathology in the form of plaques. According to Thal phase, 15 of the other 33 patients were at phase 4 or 5, whereas the remaining 18 patients were at phases 1-3. In the 20 patients with low Braak tau pathological scores (i.e. less than Braak tau stage V), amyloid pathology was mild to moderate in extent and plaques were mostly of the diffuse type with only occasional cored and neuritic plaques being present, although six patients showed more extensive amyloid deposition with more neuritic plaques, but only three of these exceeded Thal phase 3. Conversely, in those 14 patients with high Braak tau scores (V-VI), amyloid pathology was usually severe with many cored, neuritic type plaques also being present. All except two of these patients were at Thal phase 5. CAA was present in 25/34 patients, but was generally only mild to moderate in extent affecting mostly leptomeningeal arteries, particularly those in the occipital lobe. In four patients, all with extensive Alzheimer-type changes, CAA was severe and also involved parenchymal arteries. In the control subjects, some degree of tau pathology was also present in all though this did not exceed Braak tau stage II in any individual. Similarly, some amyloid plaque deposition was present in all subjects, but was usually mild to moderate, mostly in the form of diffuse plaques and did not exceed Thal phase 3 in any individual. Mild to moderate leptomeningeal CAA was present in six patients (see Table S1 ). Overall, as expected, patients with LBD showed a higher degree of both amyloid plaque scores (P = 0.001) and Thal phase (P = 0.001) than controls, and there was a significantly greater (P < 0.001) level of amyloid deposition (and higher Thal phase (P < 0.001)) in patients with LBD and concomitant AD compared to those with LBD and only limited Alzheimer pathology. However, the extent of CAA was not significantly different between either of the LBD groups.
Mean age at onset (65.0 AE 7.4 years) in LBD patients with high Braak tau stages (i.e. with concomitant AD) was significantly younger (P = 0.003) than that in those with LBD patients with limited Alzheimer pathology and low tau Braak stages (75.2 AE 8.3 years), and consequently they died at significantly earlier age (75.8 AE 7.6 years vs. 84.0 AE 8.2 years, respectively; P = 0.006); duration of disease was also shorter in LBD patients with high tau Braak stage (7.7 AE 3.4 years vs. 9.8 AE 3.7 years) but not significantly so (P = 0.175) ( Table 1) . Overall, patients with LBD had a significantly higher APOE ε4 allele frequency than controls (LBD, 25/66 alleles, 0.38; controls 0/20 alleles, 0.00; P < 0.05 by Fisher exact test). Indeed, patients with LBD with high Braak tau scores also had a significantly higher APOE ε4 allele frequency than those with low Braak tau scores (high Braak tau LBD, 17/28 alleles, 0.61; low Braak tau LBD 8/46 alleles, 0.17; P < 0.001 by Chi-square test).
There were no significant differences in age at onset, age at death or duration of illness between LBD bearing the APOE ε4 allele compared to those without the APOE ε4 allele. However, LBD patients bearing the APOE ε4 allele showed a marginally greater degree of amyloid plaque formation (P = 0.030) and degree of CAA (P = 0.050), than those without the APOE ε4 allele. Neither were there any significant differences in age at onset, age at death nor duration of illness between LBD bearing GBA1 mutation compared to those without ( Table 1) . The four LBD patients bearing GBA1 mutation did not show any differences in degree of amyloid plaque formation (P = 0.872) or degree of CAA (P = 0.364) from those 10 without GBA1 mutation.
Phosphorylated α-synuclein
Anti-psyn1175 staining was confined to LB and LN (Fig. 1) . In the SN, LB often appeared large with a dense core and a lighter staining halo (Fig. 1a) although others appeared more homogeneously immunostained, whereas in the CG, LB were smaller and displayed less morphological variation (Fig. 1b) . There was much variation in the quantity of LN between cases. In the SN (Fig. 1a) these appeared much thicker, straighter, and less evenly distributed than those in CG which appeared shorter and often punctate (Fig. 1b) .
The extent of Lewy body pathology (in terms of Braak LB stage) did not differ between LBD cases with either low or high Braak tau stage scores ( P = 0.500), or individual LB or LN scores or total score in SN (P = 0.063, P = 0.457 and P = 0.112, respectively) or CG (P = 0.641, P = 0.545 and P = 0.877, respectively) or according to the cumulative pathology score summated across both CG and SN (P = 0.323). There were no significant differences in scores for LB pathology for LBD patients with or without the APOE ε4 allele in terms of Braak LB stage (P = 0.842), or individual LB or LN scores or total score in SN (P = 0.235, P = 0.118 and P = 0.137, respectively) or CG (P = 0.870, P = 0.624 and P = 0.730, respectively) or according to the cumulative pathology score summated across both CG and SN (P = 0.392). There were also no significant differences in scores for SN degeneration (SND) pathology for LBD patients with or without the APOE ε4 allele (P = 0.573).
Likewise, there were no significant differences in scores for LB pathology for LBD patients with or without known GBA1 mutation in terms of Braak LB stage (P = 0.897), or individual LB or LN scores or total score in SN (P = 1.00, P = 0.236 and P = 0.608, respectively) or CG (P = 0.874, P = 0.368 and P = 0.467, respectively) or according to the cumulative pathology score summated across both CG and SN (P = 0.469). There were also no significant differences in scores for SND pathology for LBD patients with or without GBA1 mutation (P = 0.552).
LAMP-1, LAMP-2, CTSD and LC3A immunohistochemistry
Neurons
In the control individuals, immunoreactivity for LAMP-1, LAMP-2, CTSD and LC3A was present within the cell cytoplasm of neuromelanin containing neurones of SN (Fig. 1c, e, g, i) , and of CG (Fig. 1d, f, h, j) , and in every instance appeared diffuse and granular in appearance. Nonetheless, immunostaining varied widely in intensity between the different ALP markers in both control and LBD patients. For LAMP-1 (Fig. 1c, d ), LAMP-2 (Fig. 1e , f) and LC3A (Fig 1i, j) this was usually moderate to strong in intensity, and present throughout the cell cytoplasm, with some cases displaying a more intense perinuclear staining. However, CTSD immunostaining was generally less strong with most cases being only mild to moderately immunostained (Fig. 1g, h ). While there were individual case variations, there were no obvious group differences from the control individuals in the morphological pattern of neuronal immunostaining, or the intensity of staining, in the patients with LBD. Additionally, LC3A antibody immunolabelled nerve fibers passing through the neuropil in both CG and SN (Figs. 1i, j; 2a) .
Glial cells
Glial cells (astrocytes) within both SN and CG were variably immunostained in both controls and LBD patients (Fig. 1) . In CG, such cells usually displayed only a few weakly to moderately intensely stained granules in LAMP-1 (Fig. 1d) , LAMP-2 ( Fig. 1f) and CTSD (Fig. 1h) immunostained sections but were unstained with LC3A (Fig. 1j) antibody. However, in the SN glial cells showed moderate to strong immunostaining for LAMP-1 (Fig. 1c) and LAMP-2 ( Fig. 1e) and weak or negative immunostaining for both CTSD (Fig. 1f) and LC3A (Fig. 1i) .
Inclusion bodies
In the SN, immunopositive inclusions resembling LB were seen on LC3A-immunostained sections of 17/34 (50%) patients with LBD (Fig. 2a) . In general, these were moderately to strongly immunostained. Of these 17 patients, eight also showed LAMP-1-immunoreactive (Fig. 2b) and these too were moderately to intensely immunostained when present. Only well-formed concentric LB were immunostained, and more diffuse LB or pale bodies were not detected. Immunoreactivity for LC3A was present in the periphery of the LB (Fig. 2a) whereas in LAMP-1 immunostaining this was diffusely present throughout the LB (Fig. 2b) . No structures resembling LB were observed in LAMP-2 (Fig. 2c) or CTSD immunostaining (Fig. 2d) , and no clearly delineated LB were seen within CG with any of the four ALP markers (not shown). LC3A immunostaining also detected intracellular and extracellular neurofibrillary tangles, especially in those patients where the density of plaques and tangles were consistent with presence of coexisting AD (Fig. 2e) . In three individuals, two controls (cases #40 and 41) and one LBD patient (case #23), Marinesco bodies were observed within the nucleus of cells of the SN. Interestingly, these were strongly immunostained by CTSD antibody (Fig. 2f ), but apparently not by LAMP-1, LAMP-2 or LC3A antibodies (not shown).
Amyloid plaques
As mentioned earlier, all except one LBD patient (patient #12) and all controls showed some degree of amyloid plaques formation when immunostained with 4G8 antibody (Fig. 3a) . In most instances these were present as diffuse plaques although cored/neuritic plaques were common, particularly in those LBD patients with concomitant AD. Eighteen (of 33) LBD patients (13 of those 14 with extensive AD pathology) and five of the 10 controls showed extracellular immunoreactive structures resembling (cored) amyloid plaques, when immunostained with LAMP-1 and LAMP-2 antibodies (Fig. 3a and b , respectively). In these plaque regions, LAMP-1 and LAMP-2 glial cell activity was heavily present. Nonetheless, these ALP immunopositive plaques were relatively sparse, and far fewer than the number of plaques seen on 4G8 (amyloid) immunostaining (Fig. 3a) . No plaque immunostaining was observed with CTSD in any case, although on LC3A immunostaining a few neurites were seen within plaque regions (Fig. 3d) .
Semi-quantitative analysis
Neurons
The degree of immunostaining in nerve cells of the SN was significantly less in LBD overall compared to controls for LAMP-1 (P = 0.039) (Fig. 4a) , LAMP-2 (P = 0.001) (Fig. 4c ) and CTSD (P = 0.007) (Fig. 4e) but not for LC3A (P = 0.967) (Fig. 4g) . In CG, the degree of immunostaining of nerve cells was not significantly less in LBD overall compared to controls for LAMP-1 (p = 0.499) (Fig. 4b) , CTSD (P = 0.216) (Fig. 4f ) and LC3A (P = 0.273) (Fig. 4h) but was significantly less in LBD overall compared to controls for LAMP-2 (P = 0.016) (Fig. 4d ).
There were no significant differences between LBD patients with concomitant AD and those with only limited changes for neuronal LAMP-1 immunostaining in the SN alone (P = 0.416) or in SN or CG for LAMP-2 (P = 0.478 and P = 0.833, respectively), CTSD (P = 0.061 and P = 0.306, respectively) and LC3A (P = 0.341 and P = 0.180, respectively). 
Glial cells
The degree of immunostaining in glial cells of both the SN and CG was not significantly different in patients with LBD overall compared to controls for LAMP-1 (P = 0.649 and P = 0.534, respectively), LAMP-2 (P = 0.080 and P = 0.836, respectively), CTSD (P = 0.070 and P = 0.261, respectively) and LC3A (P = 1.00 and P = 1.00, respectively).
Similarly, there were no significant differences in the degree of immunostaining in glial cells of both the SN and CG in patients with LBD with concomitant AD and those with only limited changes for LAMP-1 (P = 0.870 and P = 0.478, respectively), LAMP-2 (P = 0.341 and P = 0.616, respectively), CTSD (P = 0.904 and P = 0.959, respectively) and LC3A (P = 1.00 and P = 1.00, respectively).
Association with genotype
Neurons
The degree of neuronal immunostaining in LBD patients with the APOE ε4 allele was not significantly different compared to those without the APOE ε4 allele for LAMP-1 in either the SN (P = 0.265) or CG (P = 0.676), LAMP-2 (P = 0.221 and P = 0.842, respectively), CTSD (P = 0.785 and P = 0.316, respectively) or LC3A (P = 0.524 and P = 0.573, respectively).
The degree of LAMP-1 immunostaining in neurons of the SN was marginally less in the four LBD patients with GBA1 mutations compared to those 10 LBD patients without (P = 0.050), but no such differences were seen in the CG (P = 0.207). Conversely, the degree of immunostaining was not significantly different in LBD patients with GBA1 mutations compared to those without for LAMP-2 in either the SN (P = 0.519) or CG (P = 0.485), CTSD (P = 0.117 and P = 0.392, respectively) or LC3A (P = 0.296 and P = 0.110, respectively).
Glial cells
The degree of glial cell immunostaining in LBD patients with the APOE ε4 allele was not significantly different compared to those without the APOE ε4 allele for LAMP-1 in either the SN or CG (P = 0.361 and P = 0.250, respectively), LAMP-2 (P = 0.434 and P = 0.456, respectively), CTSD (P = 0.870 and P = 0.573, respectively) or LC3A (P = 1.00 and P = 1.00, respectively). Similarly, the degree of glial cell immunostaining in the four LBD patients with GBA1 mutation was not significantly different compared to those 10 without GBA1 mutation for LAMP-1 in either the SN or CG (P = 0.384 and P = 0.712, respectively), LAMP-2 (P = 0.507 and P = 0.635, respectively), CTSD (P = 0.094 and P = 0.304, respectively) or LC3A (P = 1.00 and P = 1.00, respectively). 
Plaque immunostaining
There were significant differences in the number of plaques in CG immunostained by 4G8 and the four ALP antibodies (χ 2 = 134.0, P = 0.000) with the number of 4G8 immunostained plaques being far greater than those stained by all of the four ALP antibodies (P < 0.0001 in every instance). Moreover, the number of plaques immunostained by LAMP-1 and LAMP-2 antibodies was significantly greater than that immunostained by CTSD and LC3A antibodies (P < 0.0001 in every instance) whereas there were no significant differences between the number of plaques immunostained by LAMP-1 and LAMP-2 antibodies (P = 0.740 and P = 0.693, respectively) or CTSD and LC3A antibodies (P = 1.000 for both).
Correlations
Spearman rank correlations were performed between the degree of neuronal and glial cell immunostaining for LAMP-1, LAMP-2, CTSD, LC3A and psyn1175 in cells of CG and SN in the 34 LBD patients. In order to avoid type 1 errors from multiple testing, significance levels were stringently set at P < 0.01. Accordingly, and as would be anticipated, scores for LB and LN (psyn1175) severity and combined LB and LN scores all correlated significantly (P < 0.001 in each instance). Similarly, in CG, scores for LB and LN severity and combined LB and LN scores again all correlated significantly (P < 0.001 in each instance). In the SN, there were significant positive correlations between the SND score and individual scores for LB (P = 0.005) and LN (P = 0.021) pathology, and combined LB and LN scores (P = 0.006).
SND scores showed negative correlation with neuronal LAMP-1 (P = 0.010) and CTSD (P = 0.003) scores (i.e. as the degree of SND increased, so the level of immunostaining for LAMP-1 and CTSD decreased), but this association did not hold for LAMP-2 (P = 0.168) or LC3A (P = 0.641) scores. None of the individual scores for LB pathology in either the SN or CG correlated with neuronal LAMP-1, LAMP-2, CTSD or LC3A immunostaining intensity. There were significant correlations in the SN between neuronal LAMP-1 and CTSD scores (P = 0.014) and between neuronal LAMP-2 and CTSD scores (P = 0.018) but no other significant correlations were present involving other staining combinations. In the CG, were no significant intercorrelations between neuronal LAMP-1, LAMP-2, CTSD or LCA3 scores. There were no significant correlations between neuronal and glial cell scores for any of the four ALP markers, in either the SN or the CG. There was significant correlation between plaque scores in CG for LAMP-1 and LAMP-2 immunostaining (P < 0.001), but no such correlation was present between other combinations of ALP markers.
DISCUSSION
The presence of Alzheimer-type pathological changes in patients with LBD is well known. 35 In the present cohort of 34 patients with LBD, 14 (41%) patients had sufficient Alzheimer-type pathology to meet neuropathological criteria for AD with the remainder showing some degree of Alzheimer pathological changes up to, but not exceeding, Braak stage IV. Such a 'spectrum' of Alzheimer-type pathology in the present cohort is therefore entirely typical of LBD. 35 Nonetheless, of particular interest were the findings that although the presence of the APOE ε4 allele rendered a level of plaque and tangle pathology concomitant with a pathological diagnosis of AD more likely, this had no bearing on the degree of LB pathology present. Possession of GBA1 mutation also had no influence over the amount of Alzheimer-type or Lewy body pathology present. Immunostaining by LAMP-1 and LAMP-2 antibodies of plaque-like structures in many LBD patients likely represents immunoreactivity in glial cells surrounding, or included within, accompanying amyloid plaques present in many patients, especially those with concomitant AD. Barrachina and colleagues also found increased LAMP-1 immunoreactivity in glia and neurones surrounding plaques in patients with AD alone. 36 It is possible therefore that the increased LAMP-1 staining within glial cells represents an attempt to degrade the plaques. The main findings from the present study, with regard to changes in lysosomal and autophagosomal proteins in LBD, are that there is significantly less LAMP-1, LAMP-2 and CTSD immunoreactivity in the SN, but only LAMP-2 immunoreactivity in the CG, in patients with LBD compared to controls, while there are no overall differences in LC3A immunoreactivity in either CG or SN between patients with LBD and controls. The reduction in LAMP-1, LAMP-2 and CTSD immunostaining, and thus putatively fewer and/or active lysosomes present, in remaining cells of the SN in LBD suggest, on face value, an underlying impairment of the ALP. Chu et al. reported reduced LAMP-1 and CTSD in residual neuromelanin-containing cells in the SN in PD, more severely so in those cells immunoreactive for α-synuclein (i.e. with LB). 37 On the other hand, Murphy and coworkers found no changes in LAMP-1 in a group of PD and PDD patients at Braak PD stage V or less. 38 However, in a later study, as we have found here, the same authors reported decreased levels of LAMP-2, specifically LAMP-2A, in CG in the same patients featured in the earlier study, this being associated with an increase in α-synuclein. 39 Such findings imply a reduction in LAMP-2 in early stage LBD might precede that of LAMP-1 which occurs only in later disease stages. The finding in the present study of decreases in both LAMP-1 and LAMP-2 in the more severely (than CG) damaged SN would accord with this view. Interestingly, there was no difference between LAMP-1 or LAMP-2 levels in LBD patients with severe AD type (tau) pathology and those with more limited AD type (tau) pathology, implying that the additional burden of neuritic and neurofibrillary tau pathology did not aggravate changes associated with LBD pathology.
Another study employed MPTP-treated mice and cultured neuroblastoma cells, as a model of PD, and also demonstrated a reduction in LAMP-1, although this was accompanied by an increase in LC3A levels. 40 Higashi and colleagues noted increased numbers of LC3A-immunoreactive neurones in the cerebral cortex, hippocampus and amygdala in patients with DLB compared to control individuals, and LC3A protein levels were similarly increased on immunoblotting. 41 Since LC3A is degraded upon autophagosome-lysosome fusion, this increase could represent an impairment of lysosomal function, which in turn leads to the accumulation of autophagosomes and LC3A protein. Nonetheless, in the present study we were unable to show any changes in LC3A immunoreactivity in either the SN or CG. The reason for this discrepancy is not clear, although methodological and species differences might be responsible. Higashi and colleagues employed tissues from humans with LBD in cell counting based on immunohistochemistry and detected protein levels by Western blotting. 41 Dehay et al. only used the latter to detect changes in LC3A levels in mouse and cell MPTP models of PD. 40 It is therefore possible that immunohistochemistry combined with the semi-quantitative method used here to assess changes in LC3A protein levels may not have been sufficiently sensitive to detect a similar (to biochemical) change in LC3A levels as reported by others. 40, 41 On the other hand, because no LBD pathology is generated in the MPTP model, the latter model may not necessarily invoke the same pathological cascade. Furthermore, neuropathological evaluation permits only the assessment of neurones that have survived up until the point of death. Considering that autophagy is the last line of defense in preventing protein aggregation, and given the crucial role it plays in cell homeostasis, it is possible that those cells that had developed an impairment of autophagy in vivo had already died and thus could not be assessed. If this is so, then autophagy may still be impaired but in view of the lack of morphological changes in LC3A immunostaining, such deficits would more likely lie in processes downstream of autophagosome formation and maturation, perhaps in autophagosome fusion and breakdown. Nevertheless, this apparent disconnection between reduced LAMP-1 and LAMP-2 levels, and LC3A level, implies that the reduced LAMP-1/2 levels may not in fact be related to a dysfunction in autophagy. Alternatively, it is possible that reduced LAMP-1/2 levels in SN in patients with DLB is the result of neurodegeneration of the SN independent of the actual cause of this with the few nigral neurones that remain being already dead or dying cells © 2018 Japanese Society of Neuropathology protein degradation in Lewy body diseasewhich naturally would be expected to contain very few or no lysosomes. The stronger correlation, found here, between LAMP-1 and CTSD scores and SND score, than between LAMP-1 (and other ALP markers) scores and any of the Lewy pathology scores would be consistent with such a view. Moreover, the lack of any reduction in LAMP-1 in the CG would argue that LAMP-1 levels were reduced in the SN as a result of the neurodegeneration rather than a reflection of the pathophysiological process. However, if this were so, then there ought to have been similar correlations between SND score and LAMP-2 and LC3A as presumably these markers, as with LAMP-1 and CTSD, should also have been swept away in the tide of neurodegeneration affecting the SN.
Although patients with LBD with GBA1 mutations showed a marginally greater loss of LAMP-1 immunostaining in SN compared to those without, the significance of this finding is unclear given the small number of LBD patients with GBA1 mutations examined in the present study. Nonetheless, if true, it could be argued that destabilization of lysosomes due to the accumulation of glucosylceramide would lead to their increased turnover and reduced LAMP-1 levels. On the other hand, similar studies have suggested that LAMP-1 levels, and thus lysosomal numbers, are unchanged in sporadic cases of PD and DLB where deficits in glucocerebrosidase enzyme activity have been demonstrated, suggesting that it is acid hydrolase activity rather than lysosomal numbers, per se, that is affected. 38 Furthermore, other studies have described a trend toward increased LC3A levels in glucocerebrosidase deficient cells. 21, 42 In the present study, there were no differences in LC3A levels in SN or CG in GBA1 mutation cases. If the ALP was impaired, it would be anticipated that LC3A would accumulate, rather than be lost, since it is degraded by this pathway. Nonetheless, as discussed earlier, the greater reduction in SN LAMP-1 levels observed in GBA1 mutation carriers may simply be a reflection of the extreme neurodegeneration occurring in that area, although having said that, there were no significant differences in LAMP-2, CTSD or LC3A levels between GBA1 mutation carriers and non-carriers as might be anticipated were this the reason for the decline in LAMP-1. Clearly, further studies involving a greater number of mutation carriers are needed to resolve this issue. LB immunoreactive for LAMP-1 (occasionally and strongly) and LC3A (frequently but only weakly) were seen in all patients with LBD but only unambiguously so within SN where such staining was clearly present in those well-formed laminar LB but not seen in the less wellformed α-synuclein aggregates or in pale bodies. LAMP-1 immunopositive LB showed a different morphology from LC3A immunopositive LB, often displaying the distinct halo effect with a darker ring surrounding the lighter stained central core typical of well-formed LB as seen in HE preparations, whereas LC3A immunopositivity was more peripherally localized around the margins of LB. Indeed, localization of LC3A to Lewy bodies has been demonstrated previously in patients with PD 40 and DLB. 41 LB are ubiquitinated 10 and also display immunoreactivity for selective autophagy adapter proteins p62/SQSTM1 43 and NBR1. 44 Collectively, these findings suggest that lysosomes and autophagosomes might localize to LB in order to mediate autophagic clearance, or that LB derive from undegraded autophagosomes, the contents of which have condensed and coalesced into LB, once they have lost their limiting membranes. Moreover, LAMP-1-positive inclusions were found in some cases where no LC3A inclusions were detected. Given that the LAMP1 and LC3A-positive inclusions did not always cooccur, it is also possible that lysosomes have localized to LB in an attempt to degrade α-synuclein by CMA -a form of autophagy that does not involve autophagosomes.
In support of this, it was demonstrated that LAMP-2, a direct receptor for CMA-mediated degradation of α-synuclein, was similarly localized to LB. 41 However, in the present study, no immunoreactivity for LAMP-2 (or CTSD) was seen implying that the presence of particular ALP proteins, such as LAMP-1 and LC3A, is specifically related to the formation of LB, and that they are not drawn passively into the structure of LB.
In conclusion, therefore, previous efforts to establish the factors that cause accumulation of α-synuclein, the protein assimilated into the pathognomic LB of DLB, have pointed toward dysfunction of the ALP as a key contributor. In agreement with previous studies, the present investigation of the ALP found that there were less LAMP-1, LAMP-2 and CTSD proteins, and thus fewer (functional) lysosomes in the SN in DLB compared to controls, and in the SN of patients with GBA1 mutations compared to those without. No such changes were seen with LC3A. These findings support a potential role for lysosomal impairment, and consequent ALP dysfunction, but not autophagosomal function, in the pathogenesis of LBD. Nonetheless, because of discrepant results probably arising from methodological differences in assessment of LC3A (i.e. autophagosomal) activity between the present and previous studies, 40, 41 we cannot altogether dismiss the possibility that this pathway is also affected. Whether these changes in lysosomal function are centrally causative or part of the wider process of neurodegeneration within the SN is presently unclear.
